nifedipine has been researched along with debrisoquin in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belas, F; Chaudhary, AK; Cvetkovic, M; Dempsey, PJ; Fromm, MF; Kim, RB; Leake, B; Roden, DM; Roden, MM; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Kallio, J | 1 |
| Hoffmann, A; Sigusch, H | 1 |
| Henschel, L; Hoffmann, A; Sigusch, H | 1 |
| Beerahee, M; Beevers, DG; Jack, DB; Kendall, MJ; Wilkins, MR | 1 |
| Henderson, CJ; McLaughlin, LA; Scheer, N; Stanley, LA; Wolf, CR | 1 |
1 review(s) available for nifedipine and debrisoquin
| Article | Year |
|---|---|
[Heritable polymorphisms in oxidative drug metabolism].
Topics: Animals; Cytochrome P-450 Enzyme System; Debrisoquin; Humans; In Vitro Techniques; Mephenytoin; Nifedipine; Oxidation-Reduction; Pharmaceutical Preparations; Phenacetin; Polymorphism, Genetic; Rats | 1990 |
8 other study(ies) available for nifedipine and debrisoquin
| Article | Year |
|---|---|
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Male; Mice; Oxidoreductases, N-Demethylating; Pharmacokinetics; Substrate Specificity | 1999 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Verapamil but not nifedipine influences the metabolic ratio of debrisoquine hydroxylation.
Topics: Cytochrome P-450 Enzyme System; Debrisoquin; Humans; Hydroxylation; Male; Nifedipine; Verapamil | 1991 |
[The effects of verapamil and nifedipine on the biotransformation of model substances and on the indocyanine green elimination].
Topics: Adult; Biotransformation; Caffeine; Debrisoquin; Dipyrone; Humans; Indocyanine Green; Liver; Liver Circulation; Male; Nifedipine; Sulfamethazine; Verapamil | 1991 |
Twelve hour (trough) plasma nifedipine concentrations during chronic treatment with nifedipine retard.
Topics: Adult; Aged; Debrisoquin; Delayed-Action Preparations; Female; Humans; Hydroxylation; Male; Middle Aged; Nifedipine | 1987 |
Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
Topics: Animals; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochromes b5; Debrisoquin; Ethanolamines; Female; Humans; Male; Mice, Knockout; Microsomes, Liver; Nifedipine; Sex Factors; Triazolam | 2015 |